AUG 21, 2014 12:00 AM PDT

New Life Sciences Research Reveals Early Stage Treatments to Help Scientists in the Fight against Ebola

WRITTEN BY: Ilene Schneider
The Intellectual Property and Science business of Thomson Reuters released a comprehensive disease profile on Ebola Virus Disease that includes a detailed analysis of two new treatments in the pipeline and two experimental candidates approaching development. The disease profile is designed to provide greater understanding of key Ebola treatments in the drug pipeline and experimental therapies approaching development.

Ebola deaths in West Africa have exceeded the 1,000 mark since ravaging Liberia. Practitioners in Britain were recently ordered to look out for symptoms of the killer virus to stop it from taking hold in the UK, with doctors receiving new guidelines on how to deal with suspected cases. Ebola Virus Disease is particularly lethal. According to the World Health Organization, outbreaks have a fatality rate of up to 90 percent. There is currently no effective treatment.

The Thomson Reuters Ebola Disease Briefing is available free of charge through its LS Research website, a resource providing researchers with the latest news on disease insights and developing treatments, through reports and biological pathway maps. This resource offers disease profiling and comparative data to the current drug landscape for clinically devastating, relevant diseases, such as Ebola.

"Our LS Research resource is designed to place valuable scientific insights into the hands of researchers to offer new angles on understanding devastating diseases - not just as related to Ebola, but for other conditions that continue to compromise quality of life for people around the world," said Jon Brett-Harris, managing director of Thomson Reuters Life Sciences.

Through analysis using Thomson Reuters Integrity - a resource providing researchers with detailed drug R&D information across multiple disciplines - LS Research analysts identified two potential Ebola treatments in the drug pipeline: Sarepta Therapeutics' VP24 expression inhibitor known as "AVI-7537" and Tekmira's VP24 expression inhibitor known as "Ebola SNALP."

VP24 is believed to play a significant role in Ebola Virus Disease, and may have an effect on the formation and replication of the viral genome. Scientists are now exploring the inhibition of this VP24 protein as a potential treatment to block the building and reproduction of the Ebola Virus genome. Both of these treatments are currently in Phase 1 clinical trials. The LS Research site also provides comprehensive information on the disease itself.

There are also two experimental treatment approaches set to move into the pipeline. The first, ZMapp, a novel drug candidate in development by Mapp BioPharmaceutical, LeafBio, Defyru, the U.S. Government and the Public Health Agency of Canada (PHAC), is a cocktail of three different humanized monoclonal antibodies produced in nicotina plants that target the virus. The aim of this potential therapy is to halt the progression of Ebola; it was recently successful in treating two American healthcare workers infected by the outbreak in West Africa. The second is a vaccine candidate, rVSVdeltaG-SWGP-2A-MFL, being developed by the Beijing Institute of Biotechnology. It consists of a recombinant vesicular stomatitis virus expressing multiple regional fragments of the Ebola virus.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
MAY 05, 2020
Immunology
Winter the Llama: An Unlikely Hero in the Fight Against COVID-19
MAY 05, 2020
Winter the Llama: An Unlikely Hero in the Fight Against COVID-19
A new hero in the fight against COVID-19 has emerged: 4-year-old Winter, a llama that currently resides in the Belgian c ...
JUN 02, 2020
Chemistry & Physics
How Can Far-Ultraviolet Light Help Us in a Pandemic?
JUN 02, 2020
How Can Far-Ultraviolet Light Help Us in a Pandemic?
Ultraviolet (UV) (10-400 nm) light is everywhere. It constitutes 10 percent of the total electromagnetic radiation in th ...
JUN 27, 2020
Microbiology
Learning More About How Bacteria Become Dangerous
JUN 27, 2020
Learning More About How Bacteria Become Dangerous
We have to share the world with microbes; they can grow almost anywhere, from hydrothermal vents deep in the sea, to the ...
JUN 30, 2020
Plants & Animals
Consequences of Sixth Mass Extinction Threaten Humanity
JUN 30, 2020
Consequences of Sixth Mass Extinction Threaten Humanity
Many scientists have taken note of the rapid decline many of the world species, and several have declared that Earth's s ...
JUL 06, 2020
Microbiology
SARS-CoV-2 Makes Cells Sprout Infectious Tentacles
JUL 06, 2020
SARS-CoV-2 Makes Cells Sprout Infectious Tentacles
The pandemic coronavirus has caused a wide range of different symptoms, and as time goes on, we may find that it can hav ...
JUL 26, 2020
Cell & Molecular Biology
How SARS-CoV-2 Works
JUL 26, 2020
How SARS-CoV-2 Works
Cell biologist Carolyn Machamer has studied viruses for the past 35 years, and has seen outbreaks caused by several path ...
Loading Comments...